Patent Application
20240382489
The present invention relates to a liquid pharmaceutical composition comprising a dose of a compound which is ensifentrine or a pharmaceutically acceptable salt thereof.
Ensifentrine (N-(2-{(2E)-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-6,7-dihydro-2H-pyrimido[6, 1-a]isoquinolin-3(4H)-yl}ethyl)urea; also known as RPL554) is a dual PDE3/PDE4 inhibitor and is described in WO 00/58308 A1.
As a combined PDE3/PDE4 inhibitor, ensifentrine has both bronchodilatory and anti-inflammatory activity and is useful in the treatment of respiratory disorders including chronic obstructive pulmonary disease (COPD). The chemical structure of ensifentrine is shown below.
COPD is a progressive, long-term condition. Ensifentrine is typically administered to COPD patients by nebuliser as a maintenance therapy. It would be beneficial to provide a blood plasma concentration of ensifentrine having a desirable pharmacokinetic profile in COPD patients following inhalation of a liquid pharmaceutical composition suitable for inhalation.
It has been found that a liquid pharmaceutical composition comprising a dose of ensifentrine or a pharmaceutically acceptable salt thereof can provide an advantageous blood plasma concentration of ensifentrine following inhalation to a human subject having COPD.
In some embodiments, the disclosure provides a liquid pharmaceutical composition comprising a dose of a compound which is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the liquid pharmaceutical composition provides a blood plasma concentration of ensifentrine after administration by inhalation to a human subject having COPD, which blood plasma concentration of ensifentrine has:
In some embodiments, the disclosure provides an ampule comprising the liquid pharmaceutical composition. In some embodiments, further provided is a nebuliser comprising the liquid pharmaceutical composition.
In some embodiments, provided herein is a method of treating COPD in a human subject, the method comprising administering the liquid pharmaceutical composition to the human subject be inhalation.
As used herein and in the appended claims, the singular forms “a,” “and,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “an agent” includes a plurality of such agents. When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. . . . The term “comprising” (and related terms such as “comprise” or “comprises” or “having” or “including”) is not intended to exclude. An embodiment of any composition of matter, composition, method, or process, or the like, described herein, may “consist of” or “consist essentially of” the described features.
As used herein, unless stated otherwise, “%” or “percent” as used herein means percent by weight (e.g., w/w % or wt %), percent by volume (e.g., v/v % or vol %), molar percentage (e.g., mol/mol % or mol %). Preferably, “%” or “percent” as used herein means percent by weight (e.g., w/w % or wt %).
The terms “treat,” “treating,” or “treatment” as used herein, include reducing, alleviating, abating, ameliorating, managing, relieving, or lessening the symptoms associated with a disease, disease state, condition, or indication (e.g., provided herein) in either a chronic or acute therapeutic scenario. Also, treatment of a disease or disease state described herein includes the disclosure of use of such compound or composition for the treatment of such disease, disease state, disorder, or indication.
In some embodiments, the liquid pharmaceutical composition provides a blood plasma concentration of ensifentrine after administration by inhalation to a human subject having COPD, which blood plasma concentration of ensifentrine has: a mean Cmax of from about 400 pg/mL to about 720 pg/mL; and/or a mean AUC0-tau of from about 2000 pg/mL*h to about 3000 pg/mL*h; and/or a mean Tmax at from about 0.6 hours to about 1.5 hours. As such, the liquid pharmaceutical composition is suitable for providing the blood plasma concentration of ensifentrine after administration by inhalation to a human subject having COPD, for instance after administration by inhalation from a nebuliser.
Cmax, AUC0-tau and Tmax are pharmacokinetic parameters well known to the skilled person. Cmax is the maximum concentration of the compound in the blood plasma achieved following administration of the compound. Tmax is the time at which Cmax is observed. AUC is the area under the curve of the blood plasma concentration of the compound as a function of time following administration over a given period. AUC0-tau is the AUC from administration to the end of the dosing period (which may for instance be 8 hours, 12 hours or 24 hours). As used herein, tau is typically 12 hours and AUC0-tau is AUC0-12 h.
In some embodiments, the liquid pharmaceutical composition provides a blood plasma concentration of ensifentrine having a mean Cmax of from about 400 pg/mL to about 720 pg/mL after administration by inhalation to a human subject having COPD. The mean Cmax may be from about 500 pg/mL to about 600 pg/mL. For instance, the mean Cmax may be from about 500 pg/mL to about 550 pg/mL, or from about 520 pg/mL to about 525 pg/mL. In some embodiments, the Cmax is at least 150 pg/mL. In some embodiments, the Cmax is at least 170 pg/mL (e.g., at least 200 pg/mL, 250 pg/mL, 300 pg/mL, 350 pg/mL, 400 pg/mL, 450 pg/mL, or 500 pg/mL). In some embodiments, the Cmax is at most 1400 pg/mL. In some embodiments, the Cmax is at most 1350 pg/mL (e.g., 1300 pg/mL, 1200 pg/mL, 1100 pg/mL, 1000 pg/mL, 900 pg/mL, 800 pg/mL, 750 pg/mL, 700 pg/mL, or 650 pg/mL). In some embodiments, the Cmax is from about 173 pg/mL to about 1330 pg/mL.
In some embodiments, the liquid pharmaceutical composition provides a blood plasma concentration of ensifentrine having a mean AUC0-tau of from about 2000 pg/mL*h to about 3000 pg/mL*h after administration by inhalation to a human subject having COPD. The mean AUC0-tau may be from about 2300 pg/mL*h to about 2600 pg/mL*h. For instance, the mean AUC0-tau may be from about 2400 pg/mL*h to about 2500 pg/mL*h, or from about 2425 pg/mL*h to about 2475 pg/mL*h. In some embodiments, the AUC0-tau is at least 800 pg/mL*h. In some embodiments, the AUC0-tau is at least 850 pg/mL*h (e.g., at least 900 pg/mL*h, 1000 pg/mL*h, 1100 pg/mL*h, 1250 pg/mL*h, 1300 pg/mL*h, 1500 pg/mL*h, 1700 pg/mL*h, 1900 pg/mL*h, 2000 pg/mL*h, 2100 pg/mL*h, 2200 pg/mL*h, 2300 pg/mL*h, or 2400 pg/mL*h). In some embodiments, the AUC0-tau is at most 8000 pg/mL*h. In some embodiments, the AUC0-tau is at most 7500 pg/mL*h (e.g., 7000 pg/mL*h, 6500 pg/mL*h, 6000 pg/mL*h, 5500 pg/mL*h, 5000 pg/mL*h, 4500 pg/mL*h, 4000 pg/mL*h, 3500 pg/mL*h, 3000 pg/mL*h, 2750 pg/mL*h, or 2500 pg/mL*h). In some embodiments, the AUC0-tau is from about 882 pg/mL*h to about 7500 pg/mL*h.
In some embodiments, the liquid pharmaceutical composition may provide a blood plasma concentration of ensifentrine having a mean Cmax of from about 400 pg/mL to about 720 pg/mL and a mean AUC0-tau of from about 2000 pg/mL*h to about 3000 pg/mL*h after administration by inhalation to a human subject having COPD.
In some embodiments, the liquid pharmaceutical composition provides a blood plasma concentration of ensifentrine having a mean Tmax at from about 0.6 hours to about 1.5 hours after inhalation by a human subject having COPD. The mean Tmax may be at from about 0.8 hours to about 1.3 hours. For instance, the mean Tmax may be at from about 0.9 hours to about 1.1 hours, about 0.95 hours to about 1.05 hours. In some embodiments, the mean Tmax is at least 0.5 hours. In some embodiments, the mean Tmax is at least 0.6 hrs (e.g., at least 0.7 hours, 0.75 hours, 0.8 hours, 0.85 hours, 0.9 hours, 0.95 hours, or 1 hour). In some embodiments, the mean Tmax is at most 2 hours. In some embodiments, the mean Tmax is at most 1.9 hrs (e.g., at most 1.8 hours, 1.7 hours, 1.6 hours, 1.5 hours, 1.4 hours, 1.3 hours, 1.2 hours, 1.1 hours, or 1 hour). In certain embodiments, the mean Tmax is about 1 hour.
The liquid pharmaceutical composition described herein may provide a blood plasma concentration of ensifentrine after administration by inhalation to a human subject having COPD, which blood plasma concentration of ensifentrine has: a mean Cmax of from about 500 pg/mL to about 600 pg/mL; and a mean AUC0-tau of from about 2300 pg/mL*h to about 2600 pg/mL*h; and a mean Tmax at from about 0.8 hours to about 1.3 hours. The blood plasma concentration of ensifentrine may have: a mean Cmax of from about 510 pg/mL to about 530 pg/mL; and a mean AUC0-tau of from about 2350 pg/mL*h to about 3550 pg/mL*h; and a mean Tmax at from about 0.9 hours to about 1.1 hours.
As used herein, the term “about” may represent a variation of ±10% of the stated value.
The mean characteristics of the blood plasma concentration provided in human subjects with COPD may be determined based on the observed mean blood plasma concentration of ensifentrine following administration of the liquid pharmaceutical composition by inhalation to a sample of human subjects having COPD. Typically, the mean Cmax, mean AUC0-tau and mean Tmax are as measured by determining the blood plasma concentration in a sample of human subjects having COPD at intervals after administration of the liquid pharmaceutical composition. The sample of human subjects may comprise from 100 to 1000 human subjects, for instance 300 human subjects. The human subjects in the sample may have ages in the range of 45 to 75 years.
The skilled person is aware of the suitable intervals for measuring blood plasma concentration following inhalation of a liquid pharmaceutical composition. In some embodiments, the intervals are at two or more of −0.5 hours (±0.5 h, i.e. pre-dose), 0.5 h (±0.25 h), 1.0 h (±0.5 h), 1.5 h (±0.5 h), 2.0 h (±0.5 h) 2.5 h (±0.5 h), 3.0 h (±0.5 h), 4.0 h (±1 h), 6.0 h (±1 h), 8.0 h (±1 h), 10.0 h (±1 h), 12.0 h (±1 h), 24.0 h (±1 h), 36.0 h (±1 h), 48.0 h (±1 h), 56.0 h (±1 h) and 60.0 h (±1 h) after administration of the liquid pharmaceutical composition. The intervals may be at two or more of−0.5 hours (±0.5 h, i.e. pre-dose), 1.0 h (±0.5 h), 2.0 h (±0.5 h), 3.0 h (±0.5 h), 4.0 h (±1 h), 12.0 h (±1 h), 24.0 h (±1 h), 36.0 h (±1 h), 48.0 h (±1 h), and 56.0 h (±1 h) after administration of the liquid pharmaceutical composition. For instance, the intervals may be at −0.5 hours (±0.5 h, i.e. pre-dose), 0.5 h (±0.25 h), 1.0 h (±0.5 h), 2.0 h (±0.5 h), 3.0 h (±0.5 h), 4.0 h (±1 h) and 12.0 h (±1 h).
In some embodiments, the blood plasma concentration is determined using an analytical method having an LLOQ of no greater than about 5.0 pg/mL.
Administration of the liquid pharmaceutical composition by inhalation to a human subject can comprise administration of the liquid pharmaceutical composition to the human subject by inhalation from a nebuliser. Nebulisers aerosolise a liquid pharmaceutical composition into an aerosol that is inhaled into a human subject's respiratory tract. Examples of nebulisers include a soft mist nebuliser, a vibrating mesh nebuliser, a jet nebuliser and an ultrasonic wave nebuliser. Suitable nebuliser devices include the Philips I-nebTM (Philips), the Philips SideStream (Philips), the AeroNeb® (Philips), the Philips InnoSpire Go (Philips), the Pari LC Sprint (Pari GmbH), the AERxRTM Pulmonary Delivery System (Aradigm Corp) and the Pari LC Plus Reusable Nebuliser (Pari GmbH). The nebuliser may for instance be a PARI LC Sprint jet nebuliser with a PARI Vios® PRO Aerosol Delivery System PARI BOY® compressor. The liquid pharmaceutical composition may be inhaled via the nebuliser for from 1 to 15 minutes, for instance from 5 to 10 minutes.
In some embodiments, the mean Cmax, mean AUC0-tau and mean Tmax may be as measured by determining the mean blood plasma concentration in a sample of 300 human subjects having COPD at intervals after administration of the liquid pharmaceutical composition, wherein the human subjects in the sample may have ages in the range of 45 to 75 years and wherein the liquid pharmaceutical composition may be inhaled via the nebuliser for from 1 to 15 minutes (for instance about 7 minutes).
The human subjects may have moderate COPD.
In some embodiments, the human subject is receiving the compound as a maintenance therapy. The compound may be administered to the human subject once, twice or three times daily. In some embodiments, the compound is administered to the human subject once daily. In some embodiments, the compound is administered to the human subject twice daily. In some embodiments, the compound is administered to the human subject 3 times daily (e.g., at most 3 times daily). The compound is preferably administered as a twice-daily maintenance therapy.
In some embodiments, the liquid pharmaceutical composition comprises a dose of a compound which is ensifentrine or a pharmaceutically acceptable salt thereof. In some embodiments, the dose is from about 2 mg to about 4 mg of the compound.
For instance, the dose may be from 2.5 mg to 3.5 mg of the compound. The dose may be from 2.8 mg to 3.2 mg of the compound. In some embodiments, the dose is about 3 mg of the compound, for example about 3.0 mg.
In some embodiments, the dose may be from 2.8 mg to 3.2 mg of ensifentrine (i.e., ensifentrine free base). In some embodiments, the dose is about 3 mg of ensifentrine, for example 3.0 mg of ensifentrine.
In some embodiments, the concentration of the compound in the liquid pharmaceutical composition is from 0.8 to 1.6 mg/mL. For instance, in some embodiments the liquid pharmaceutical composition comprises ensifentrine at a concentration of from 1.0 to 1.4 mg/mL. In some embodiments, the liquid pharmaceutical composition may comprise ensifentrine at a concentration of from 1.1 to 1.3 mg/mL. In some embodiments, the liquid pharmaceutical composition may comprise about 1.2 mg/mL ensifentrine.
In some embodiments, inhalation of the liquid pharmaceutical composition comprises inhalation only of a portion of the liquid pharmaceutical composition. As such, in some embodiments, only a portion of the liquid pharmaceutical composition is typically delivered to the patient, for instance due to a remainder of the liquid pharmaceutical composition remaining in a nebuliser used to deliver the liquid pharmaceutical composition by inhalation. The portion of the liquid pharmaceutical composition delivered to the lungs of the patient from a nebuliser may be from 20% to 40% by volume of the liquid pharmaceutical composition originally present in the nebuliser prior to administration. The portion of the liquid pharmaceutical composition delivered to the lungs of the patient from a nebuliser may be from 25 to 35% by volume of the liquid pharmaceutical composition originally present in the nebuliser prior to administration, for instance from 29 to 33% by volume or about 31% by volume. As such the mean delivered dose of the compound inhaled by the human subject may be from 20 to 40%, from 25 to 35%, or from 29 to 33% of the overall dose present in the liquid pharmaceutical composition prior to administration. In some embodiments, the mean delivered dose of the compound inhaled by the human subject may be at least 20% (e.g., at least 22%, 24%, 25%, 26%, 27%, 28%, 29%, or 30%) by volume of the overall dose present in the liquid pharmaceutical composition prior to administration. In some embodiments, the mean delivered dose of the compound inhaled by the human subject may be at most 40% (e.g., at most 38%, 36%, 34%, 33%, 32%, 31%, or 30%) by volume of the overall dose present in the liquid pharmaceutical composition prior to administration. In some embodiments, the mean delivered dose of the compound inhaled by the human subject may be about 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, or 33% by volume of the overall dose present in the liquid pharmaceutical composition prior to administration.
The mean delivered dose of the compound (e.g., the mean delivered dose of ensifentrine free base) may be from 0.7 to 1.1 mg when administered using a nebuliser. In some embodiments, the mean delivered dose may be from 0.8 to 1.0 mg, for instance from 0.90 to 0.95 mg. In some embodiments, the mean delivered dose of the compound is at least 0.7 mg (e.g., at least 0.75 mg, 0.8 mg, 0.85 mg, 0.875 mg, 0.9 mg, 0.91 mg, 0.92 mg, or 0.93 mg). In some embodiments, the mean delivered dose of the compound is at most 1.1 mg (e.g., at most 1.05 mg, 1 mg, 0.975 mg, 0.95 mg, or 0.94 mg). In some embodiments, the mean delivered dose of the compound is about 0.9 mg, 0.91 mg, 0.92 mg, 0.93 mg, or 0.94 mg. In some embodiments, the mean delivered dose of the compound is about 0.933 mg.
In some embodiments, the nebuliser is a jet nebuliser. The liquid pharmaceutical composition is typically suitable for providing the mean Cmax, mean AUC0-tau and mean Tmax defined herein following delivery from a nebulizer as described above.
The disclosure also provides a liquid pharmaceutical composition as defined herein, which liquid pharmaceutical composition provides a mean delivered dose of from 0.7 to 1.1 mg of the compound when administered using a nebuliser. The mean delivered dose may be from 0.8 to 1.0 mg, for instance from 0.90 to 0.95 mg. In some embodiments, the mean delivered dose of the compound is at least 0.7 mg (e.g., at least 0.75 mg, 0.8 mg, 0.85 mg, 0.875 mg, 0.9 mg, 0.91 mg, 0.92 mg, or 0.93 mg). In some embodiments, the mean delivered dose of the compound is at most 1.1 mg (e.g., at most 1.05 mg, 1 mg, 0.975 mg, 0.95 mg, or 0.94 mg). In some embodiments, the mean delivered dose of the compound is about 0.9 mg, 0.91 mg, 0.92 mg, 0.93 mg, or 0.94 mg. In some embodiments, the mean delivered dose of the compound is about 0.933 mg.
In some embodiments, the liquid pharmaceutical composition provides a mean increase in baseline FEV1 of at least 20 mL after administration by inhalation to the human subject. For instance, the liquid pharmaceutical composition may provide a mean increase in baseline FEV1 of at least 30 mL after administration by inhalation to the human subject. Typically, as used herein, FEV1 is determined as set out in the article Standardisation of Spirometry, Eur J 2005; 26; 319-338.
The liquid pharmaceutical may comprise a suspension of particles. The liquid pharmaceutical composition may comprise a diluent. The liquid pharmaceutical composition may comprise (a) a suspension of particles comprising the compound and (b) a diluent. In some embodiments, the diluent is water. It may be the case that some or all of the particles comprising the compound in the liquid pharmaceutical composition have settled to the bottom of a receptacle containing the liquid pharmaceutical composition, for instance after storage for a period of time. The particles comprising the compound may be re-suspended in any suitable way, for instance by agitation of the sterile liquid pharmaceutical composition.
The particles comprising the compound typically have a Dv50 of from about 0.2 μm to about 5.0 μm. For instance, the particles comprising the compound may have a Dv50 of from about 1.0 μm to about 2.2 μm, or from about 1.1 μm to about 1.5 μm.
Particle sizes are described herein by reference to the Dv50 value, which is the median particle size for a volume distribution. Thus, half the volume of the particles have diameters of less than the Dv50 value and half the volume of the particles have diameters of greater than the Dv50 value. This is a well-known manner in which to describe particle size distributions. The parameters of Dv10 and Dv90 may also be used to characterise a particle size distribution of a sample. 10% of the volume of particles have a diameter of less than the Dv10 value. 90% of the volume of the particles have a diameter of less than the Dv90 value.
The particles comprising the compound typically have a Dv10 of from about 0.3 μm to about 0.9 μm and/or a Dv90 of from about 2.3 μm to about 4.5 μm.
For instance, the particles comprising the compound may have: a Dv10 of from about 0.3 μm to about 0.9 μm; and a Dv50 of from about 1.0 μm to about 2.2 μm; and a Dv90 of from about 2.3 μm to about 4.5 μm.
The technique used to measure the Dv10, Dv50 and Dv90 values as stated herein is typically laser diffraction. The particle size distribution of the particles comprising the compound may be as measured by laser diffraction using a wet powder dispersion system. For instance, the particle size distribution can be measured by laser diffraction using a Malvern Spraytec in conjunction with a wet dispersion cell. Typically, the instrument parameters for the Malvern Spraytec are as follows:
The ensifentrine particles may be produced by any pharmaceutically acceptable size reduction process or particle size controlled production process. For instance, the particles may be produced by spray-drying a solution of ensifentrine, by controlled crystallisation, or by size reduction of a solid form of ensifentrine, for example by air jet milling, mechanical micronisation or media milling.
The particles comprising the compound typically comprise ensifentrine (i.e., ensifentrine free base). The particles comprising the compound may comprise at least 90 wt % ensifentrine free base relative to the total weight of the particles, for instance at least 95 wt % ensifentrine. In some embodiments, the particles comprise at least 90 wt % (e.g., at least 91 wt %, 92 wt %, 93 wt %, 94 wt %, 95 wt %, 96 wt %, 97 wt %, 98 wt %, 99 wt %, or 99.5 wt %) ensifentrine free base. In some embodiments, the particles comprise at most 99.9 wt % (e.g., at most 99.7 wt %, 99.5 wt %, 99 wt %, or 98 wt %) ensifentrine free base. The particles may comprise at least 99 wt % ensifentrine. The particles may consist of ensifentrine.
The compound is typically in crystalline form. The particles comprising the compound typically comprise at least 90 wt % ensifentrine free base Form I relative to the total weight of the particles. Ensifentrine free base Form I is a crystalline polymorph of ensifentrine (crystalline polymorph Form I) which typically has a powder X-ray diffraction pattern comprising characteristic peaks at 10.1° and 12.9° ±0.1° 2θ. As stated herein, values of 2θare typically as measured using an X-ray wavelength of CuKα radiation (λ=1.5406 Å). The powder X-ray diffraction pattern of Form I typically further comprises characteristics peaks at 15.3° and 17.6° ±0.1° 2θ. Form I of ensifentrine may have a powder X-ray diffraction pattern comprising at least 5 characteristic peaks selected from 6.4°, 10.1°, 12.6°, 12.9°, 13.6°, 14.2°, 14.7°, 15.3°, 15.4°, 15.8°, 17.0°, 17.6°, 18.9°, 20.9°, 22.4°, 22.8° and 28.7° ±0.1° 2θ. Crystalline polymorph Form I typically has a differential scanning calorimetry trace showing a maximum at 248° C.
The particles comprising the compound typically comprise at least 95 wt % or at least 99 wt % of ensifentrine crystalline polymorph Form I relative to the total weight of the particles. In some embodiments, the particles comprising the compound comprise at least 90 wt % (e.g., at least 91 wt %, 93 wt %, 95 wt %, 96 wt %, 97 wt %, 98 wt %, 99 wt %, or 99.5 wt %) of ensifentrine crystalline polymorph Form I relative to the total weight of the particles. In some embodiments, the particles comprising the compound comprise from about 90 wt % to about 99.9 wt %, about 92 wt %, to about 99.9 wt %, about 94 wt % to about 99.9 wt %, or about 95 wt % to about 99 wt % of ensifentrine crystalline polymorph Form I relative to the total weight of the particles. The particles of the compound may consist essentially of ensifentrine crystalline polymorph Form I.
In some embodiments, the liquid pharmaceutical composition comprises, relative to the total weight of the liquid pharmaceutical composition:
The liquid pharmaceutical composition may optionally further comprise (v) a tonicity adjuster at a concentration from 6.0 to 12.0 mg/mL. In some embodiments, the liquid pharmaceutical composition comprises (v) a tonicity adjuster at a concentration of from about 6 mg/mL to about 10 mg/mL. In some embodiments, the liquid pharmaceutical composition comprises (v) a tonicity adjuster at concentration of from about 6 mg/mL to about 9 mg/mL. In some embodiments, the liquid pharmaceutical composition comprises the tonicity adjuster at a concentration of about 6 mg/mL, 7 mg/mL, 8 mg/mL, 8.2 mg/mL, 8.4 mg/mL, 8.6 mg/mL, 8.8 mg/mL, 9 mg/mL or 10 mg/mL. In some embodiments, the liquid pharmaceutical composition comprises the tonicity adjuster in an amount of about 8.6 mg/mL. The tonicity adjuster is typically sodium chloride.
The liquid pharmaceutical compositions may comprise the surfactant in an amount of from about (e.g., concentration of about) 0.1 to about 1.0 mg/mL. In some embodiments, the surfactant is present in an amount of at least 0.05 mg/mL. In some embodiments, the surfactant is present in an amount of at least 0.1 mg/mL (e.g., at least about 0.15 mg/mL, 0.2 mg/mL, 0.25 mg/mL, 0.3 mg/mL, 0.35 mg/mL, or 0.4 mg/mL). In some embodiments the surfactant is present in an amount of at most 1 mg/mL (e.g., at most 0.9 mg/mL, 0.8 mg/mL, 0.7 mg/mL, 0.65 mg/mL, 0.6 mg/mL, 0.55 mg/mL, or 0.5 mg/mL). In some embodiments, the surfactant is present in an amount of about 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL, 0.6 mg/mL, or 0.7 mg/mL. In some embodiments, the surfactant is present in an amount of about 0.55 mg/mL.
The liquid pharmaceutical compositions may comprise the buffer in an amount (e.g., a concentration of) about from about 1 mg/mL to about 2 mg/mL. In some embodiments, the buffer is present in an amount of at least 1 mg/ml (e.g., 1.1 mg/mL, 1.2 mg/mL, 1.3 mg/mL, 1.4 mg/mL, 1.5 mg/mL, 1.6 mg/mL, 1.7 mg/mL, 1.8 mg/mL, 1.9 mg/mL, or 2.0 mg/mL). In some embodiments, the buffer is present in an amount of at most 2 mg/ml (e.g., 1.9 mg/mL, 1.8 mg/mL, 1.7 mg/mL, 1.6 mg/mL, 1.5 mg/mL, or 1.4 mg/mL). In some embodiments, the buffer is present in an amount of about 1 mg/mL, 1.1 mg/mL, 1.2 mg/mL, 1.3 mg/mL, 1.4 mg/mL, 1.5 mg/mL, 1.6 mg/mL, or 1.7 mg/mL. In some embodiments, the buffer is present in an amount of about 1.6 mg/mL.
The liquid pharmaceutical composition may comprise, relative to the total weight of the liquid pharmaceutical composition: (i) ensifentrine particles at a concentration of from 1.0 to 1.4 mg/mL, which ensifentrine particles have a Dv50 of from about 1.0 μm to about 2.2 μm and optionally have a Dv10 of from about 0.3 μm to about 0.9 μm and a Dv90 of from about 2.3 μm to about 4.5 μm; (ii) one or more surfactants at a total concentration of from 0.4 to 0.7 mg/ml; (iii) one or more buffers at a total concentration of from 1.4 to 1.8 mg/ml; (iv) water; and a tonicity adjuster at a concentration from 7.0 to 10.0 mg/mL.
The liquid pharmaceutical composition may comprise at least 95 wt % or at least 99 wt % of (i), (ii), (iii), (iv) and optionally (v) relative to the total weight of the liquid pharmaceutical composition.
Examples of buffers include a citrate buffer, a phosphate buffer, an acetate buffer, and a bicarbonate buffer. Preferably, the one or more buffers comprise a phosphate buffer, for instance sodium dihydrogen phosphate dihydrate and/or disodium phosphate dihydrate.
Examples of surfactants include lecithin, oleic acid, polyoxyethylene glycol alkyl ethers (for instance PEG 300, PEG 600, PEG 1000, Brij 30, Brij 35, Brij 56, Brij 76 and Brij 97), polypropylene glycol (for instance PPG 2000), glucoside alkyl ethers, polyoxyethylene glycol octylphenol ethers, polyoxyethylene glycol alkylphenol ethers, glycerol alkyl esters, polyoxyethylene glycol sorbitan alkyl esters (polysorbates, for instance polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80), sorbitan alkyl esters (for instance sorbitan monolaurate (Span 20), sorbitan monooleate (Span 80) and sorbitan trioleate (Span 85)), cocamide MEA, cocamide DEA, dodecyldimethylamine oxide, block copolymers of polyethylene glycol and polypropylene glycol (poloxamers), block copolymers of polyethylene glycol and polypropylene oxide (for instance Pluronic surfactants), polyvinyl pyrrolidone K25, polyvinyl alcohol, oligolactic acid, sodium dioctyl sulfosuccinate and polyethoxylated tallow amine (POEA).
Preferably, the one or more surfactants comprise a polysorbate and/or a sorbitan alkyl ester. The one or more surfactants may for instance comprise polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate) or polysorbate 80 (polyoxyethylene (20) sorbitan monooleate). The one or more surfactants may for instance comprise sorbitan monolaurate (Span 20), sorbitan monooleate (Span 80) or sorbitan trioleate (Span 85). Preferably, the one or more buffers comprise polysorbate 20 (Tween 20) and/or sorbitan monolaurate (Span 20).
The liquid pharmaceutical composition may comprise, relative to the total weight of the liquid pharmaceutical composition: (i) ensifentrine particles at a concentration of from 1.0 to 1.4 mg/mL, which ensifentrine particles have a Dv50 of from about 1.0 μm to about 2.2 μm and optionally have a Dv10 of from about 0.3 μm to about 0.9 μm and a Dv90 of from about 2.3 μm to about 4.5 μm; (ii) one or more surfactants at a total concentration of from 0.4 to 0.7 mg/mL, which one or more surfactants are selected from a polysorbate and/or a sorbitan alkyl ester; (iii) one or more buffers at a total concentration of from 1.4 to 1.8 mg/mL, which one or more buffers are selected from phosphate buffers; (iv) water; and sodium at a concentration from 7.0 to 10.0 mg/mL.
The ensifentrine particles are particles comprising ensifentrine free base. The ensifentrine particles typically comprise at least 90.0 wt % of ensifentrine, preferably at least 95.0 wt %. The ensifentrine particles may consist essentially of ensifentrine or may consist of ensifentrine. The ensifentrine particles typically comprise at least 90.0 wt % or at least 95.0 wt % of crystalline polymorph Form I of ensifentrine as defined herein. For instance, the ensifentrine particles may comprise at least 90 wt % of ensifentrine in the form of crystalline polymorph Form I having an powder X-ray diffraction pattern comprising at least 5 characteristic peaks selected from 6.4°, 10.1°, 12.6°, 12.9°, 13.6°, 14.2°, 14.7°, 15.3°, 15.4°, 15.8°, 17.0°, 17.6°, 18.9°, 20.9°, 22.4°, 22.8° and 28.7° ±0.1° 2θ.
In some embodiments, the ensifentrine particles further comprise a favourable impurity profile.
In some embodiments, the ensifentrine particles further comprise a biuret impurity of formula (A). In some embodiments, the biuret impurity of formula (A) is present in an amount of at least 0.00 wt % (e.g., at least 0.05 wt %, 0.1 wt %, 0.15 wt %, 0.2 wt %, 0.25 wt %, 0.3 wt %, 0.35 wt %, 0.4 wt %, or 0.5 wt %). In some embodiments, the biuret impurity of formula (A) is present in an amount of no more than 1 wt % (e.g., no more than 0.9 wt %, 0.8 wt %, 0.7 wt %, 0.6 wt %, or 0.5 wt %). In some embodiments, the biuret impurity of formula (A) is present in an amount of about 0.1 wt %, 0.2 wt %, 0.3 wt %, 0.4 wt %, 0.5 wt %, or 0.6 wt %. In some embodiments, the biuret impurity of formula (A) is present in an amount of about 0 wt % to about 0.5 wt %.
In some embodiments, the ensifentrine particles further comprise 1,3-bis(2-(2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6, 1-a]isoquinolin-3(4H)-yl)ethyl)urea (BMIQU). In some embodiments, the BMIQU is present in an amount of about 0 wt % to about 0.6 wt %. In some embodiments, the BMIQU is present in an amount of at least 0 wt % (e.g., at least 0.1 wt %, 0.2 wt %, 0.3 wt %, 0.4 wt %, 0.5 wt %, or 0.6 wt %). In some embodiments, the BMIQU is present in an amount of at most 1 wt % (e.g., at most 0.9 wt %, 0.8 wt %, 0.7 wt % 0.6 wt %, or 0.5 wt %). In some embodiments, the BMIQU is present in an amount of about 0 wt %, 0.1 wt %, 0.2 wt %, 0.3 wt %, 0.4 wt %, 0.5 wt %, or 0.6 wt %. In some embodiments, the BMIQU is present in an amount of about 0.02 wt % to about 0.06 wt %.
In some embodiments, the ensifentrine particles further comprise 1-(2-(9-hydroxy-2-(mesitylimino)-10-methoxy-4-oxo-6,7-dihydro-2H-pyrimido[6, 1-a]isoquinolin-3(4H)-yl)ethyl)urea (9-des- methyl impurity) and/or 1-(2-(10-hydroxy-2-(mesitylimino)-9-methoxy-4-oxo-6,7-dihydro-2H-pyrimido[6, 1-a]isoquinolin-3(4H)-yl)ethyl)urea (10-des-methyl impurity).
In some embodiments, the 9-des-methyl impurity is present in an amount of from about 0 wt % to about 0.1 wt %. In some embodiments, the 9-des-methyl impurity is present in an amount of at least 0 wt % (e.g., at least 0.01 wt %, 0.02 wt %, 0.03 wt %, 0.04 wt %, 0.05 wt %, 0.06 wt %, 0.07 wt %, 0.08 wt %, 0.09 wt %, or 0.1 wt %). In some embodiments, the 9-des-methyl impurity present in an amount of no more than (0.2 wt % (e.g., no more than 0.18 wt %, 0.16 wt %, 0.14 wt %, 0.12 wt %, 0.1 wt %, or 0.08 wt %). In some embodiments, the 9-des-methyl impurity is present in an amount of about 0.01 wt %, 0.02 wt %, 0.03 wt %, 0.04 wt %, 0.05 wt %, 0.06 wt %, 0.07 wt %, 0.08 wt %, 0.09 wt %, or 0.1 wt %. In some embodiments, the ensifentrine particles comprise from about 0.05 wt % to about 0.09 wt % of the 9-des-methyl impurity.
In some embodiments, the 10-des-methyl impurity is present in an amount of from about 0 wt % to about 0.1 wt %. In some embodiments, the 10-des-methyl impurity is present in an amount of at least 0 wt % (e.g., at least 0.01 wt %, 0.02 wt %, 0.03 wt %, 0.04 wt %, 0.05 wt %, 0.06 wt %, 0.07 wt %, 0.08 wt %, 0.09 wt %, or 0.1 wt %). In some embodiments, the 10-des-methyl impurity present in an amount of no more than (0.2 wt % (e.g., no more than 0.18 wt %, 0.16 wt %, 0.14 wt %, 0.12 wt %, 0.1 wt %, or 0.08 wt %). In some embodiments, the 10-des-methyl impurity is present in an amount of about 0.01 wt %, 0.02 wt %, 0.03 wt %, 0.04 wt %, 0.05 wt %, 0.06 wt %, 0.07 wt %, 0.08 wt %, 0.09 wt %, or 0.1 wt %. In certain embodiments, the ensifentrine particles comprise from about 0.01 wt % to about 0.04 wt % of the 10-des-methyl impurity.
In some instances, the wt % described herein are relative to the total weight of ensifentrine.
In some instances, the ensifentrine particles further comprise (E)-2-(mesitylimino)-9,10-dimethoxy-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isoquinolin-4-one (compound (I)) and/or (E)-3-(2-aminoethyl)-2-(mesitylimino)-9,10-dimethoxy-2,3,6,7-tetrahydro-4H-pyrimido[6,1-a]isoquinolin-4-one (compound (IV)), the structures of which are shown below. The particulate composition typically comprises neither compound (I) nor compound (IV), or the particulate composition comprises less than 0.04 wt % total of compound (I) and compound (IV) relative to the total weight of ensifentrine.
The liquid pharmaceutical composition may comprise, relative to the total weight of the liquid pharmaceutical composition:
The liquid pharmaceutical composition may comprise, relative to the total weight of the liquid pharmaceutical composition:
The liquid pharmaceutical composition may comprise, relative to the total weight of the liquid pharmaceutical composition:
Typically, the total volume of the liquid pharmaceutical composition is from 2.0 to 3.0 mL. For instance, the total volume of the liquid pharmaceutical composition may be about 2.5 mL. In some embodiments, the total volume of the liquid pharmaceutical composition, such as the total volume in an ampule comprising the composition, is about 2.6 mL (e.g., 2.62 mL).
The invention also provides a liquid pharmaceutical composition comprising, relative to the total weight of the liquid pharmaceutical composition:
The ampule typically comprises from 2.0 to 3.0 mL of the liquid pharmaceutical composition. The nebuliser comprises the liquid pharmaceutical composition, and the liquid pharmaceutical composition is typically comprised in an ampule. The nebuliser may be a soft mist nebuliser, a vibrating mesh nebuliser, a jet nebuliser or an ultrasonic wave nebuliser. The nebuliser is typically a jet nebuliser. The nebuliser may for instance be a PARI LC Sprint jet nebulizer with a PARI Vios® PRO Aerosol Delivery System PARI BOY® compressor.
In some embodiments, provided herein are methods of treating COPD in a subject in need thereof. The method of treating COPD in a human subject comprises administering the liquid pharmaceutical composition to the human subject by inhalation.
In some embodiments, provided herein are methods of treating moderate COPD in a human subject in need thereof. In some embodiments, the method of treating moderate COPD comprises administering the liquid pharmaceutical composition to the human subject by inhalation.
In some embodiments, provided herein are methods if increasing trough lung function in a human subject having COPD. In some embodiments, the method of increasing trough lung function comprises administering the liquid pharmaceutical composition to the human subject by inhalation.
The method may comprise increasing morning trough lung function (i.e., trough lung function following sleep). Morning trough lung function can be measured by determining the FEV1 of the patient shortly before the morning administration of the compound as part of the maintenance therapy. For instance, FEV1 may be measured less than an hour before the morning administration of the compound. Morning trough FEV1 may be the FEV1 as measured between 11.5 and 12 hours following the prior evening dose.
An increase in trough lung function in a patient suffering from COPD is typically determined by measuring in increase in trough FEV1, i.e., the FEV1 of the patient shortly before administration of the compound as part of the maintenance therapy. In some embodiments, trough lung function is increased by at least 20 mL (e.g., at least 25 mL, 30 mL, 35 mL, 40 mL, 45 mL, 50 mL, or 55 mL). In some instances, the increase is measured after a certain period of time following a prior administration of the liquid pharmaceutical composition compared to the FEV1 of the human subject prior to a first administration of the liquid pharmaceutical composition. In some embodiments, the period of time is about 11.5 to about 12 hours.
In some embodiments, provided herein are methods of decreasing the frequency of COPD exacerbations in a subject in need thereof. In some embodiments, the method of decreasing the frequency of COPD exacerbations in a human subject in need thereof comprise administering the liquid pharmaceutical composition to the human subject by inhalation.
In some embodiments, the COPD exacerbations are decreased by at least 30% (e.g., at least 32%, 34%, 36%, 40%, 45%, or 50%) compared to the frequency of the COPD exacerbation in an untreated subject and not administered the composition.
In some embodiments, the methods comprise increasing the time to a first COPD exacerbation in the human subject. Accordingly, the patient may not have yet experienced a COPD exacerbation and the compound may increase the time until the patient experiences a first COPD exacerbation (i.e., the first COPD exacerbation is delayed). The compound may accordingly reduce the risk of COPD exacerbations in a COPD patient.
The COPD exacerbations typically comprise one or more of dyspnea (breathlessness), increased coughing, increased sputum volume, sputum purulence, wheezing, sore throat, a cold, and fever. Sputum purulence is a change in the colour of spontaneously expectorated samples from uncoloured to yellow-green. The COPD exacerbation may last for at least two days.
A COPD exacerbation may comprise (A) worsening of two or more of the following major symptoms for at least two consecutive days: dyspnea, sputum volume and sputum purulence or (B) worsening of any one major symptom together with any one of the following minor symptoms for at least two consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever (oral temperature >37.5° C.) without other cause and increased cough. For instance, a COPD exacerbation may comprise worsening of two or more of the major symptoms (dyspnea, sputum volume and sputum purulence) for at least two consecutive days.
A COPD exacerbation may be a moderate COPD exacerbation or a severe COPD exacerbation. A moderate exacerbation is defined as worsening symptoms of COPD (as defined above) requiring a minimum of three days of treatment with oral/systemic corticosteroids and/or antibiotics. A severe exacerbation is defined as worsening symptoms of COPD (as defined above) requiring in-patient hospitalization. The compound may reduce the severity of COPD exacerbations in a patient, and accordingly the compound may be for use in preventing severe COPD exacerbations in a patient. For instance, the patient may experience no severe COPD exacerbations in the year following first administration of the compound.
The compound may lengthen the time to a COPD exacerbation. For instance, it may increase the time to an exacerbation by two or more months.
Typically, a therapeutically effective amount of the liquid pharmaceutical composition is administered to the human subject by inhalation.
The COPD is typically moderate COPD or severe COPD. In some instances, the COPD is moderate COPD. In some embodiments, the COPD is severe COPD. The above stages of COPD can be classified as set out below, where FEV1 is forced expiratory volume in 1 second and FVC is forced vital capacity.
In each case the actual FEV1 for the human subject is compared with a predicted FEV1 value based on factors such as age and height of the human subject. These predicted values are readily available to the skilled person, for instance from the National Health and Nutrition Examination Survey III (Hankinson JL, Odencrantz JR, Fedan KB. Spirometry reference values from a sample of the general U.S. Population. Am J Respir Crit Care. 1999;159:179-187). Examples of equations for calculating the predicted FEV1 (in L) for a human subject are as follows, where H is height (cm) and A is age (yrs):
The FEV1 and FVC used to determine the severity of COPD in a human subject are measured by carrying out spirometry shortly after the administration of an adequate dose of at least one short-acting inhaled bronchodilator. Typically, measurement of FEV1 and FVC for determining COPD disease severity is done between 15 and 30 minutes following administration of salbutamol (albuterol).
Typically, as used herein, FEV1 and FVC are determined as set out in the article Standardisation of spirometry, Eur J 2005; 26; 319-338.
The human subject may have been determined to have moderate COPD by measuring FEV1/FVC<0.7 and 50%≤FEV1<80% predicted FEV1 value, where FEV1 is forced expiratory volume in 1 second and FVC is forced vital capacity as measured between 15 and 30 minutes after a dose of a bronchodilator, optionally wherein the bronchodilator is salbutamol. The human subject may have been determined to have severe COPD by measuring FEV1/FVC<0.7 and 30%≤FEV1<50% predicted, where FEV1 is forced expiratory volume in 1 second and FVC is forced vital capacity as measured between 15 and 30 minutes after a dose of a bronchodilator, optionally wherein the bronchodilator is salbutamol. The determination of the human subject's COPD severity may take place at least 1 day prior to the first administration of the compound.
In some embodiments, the methods herein comprise increasing average FEV1 of the human subject by at least 50 mL (e.g., 12 weeks following administration). In some embodiments, the methods herein comprise increasing average FEV1 of the human subject by at least 60 mL (e.g., at least 70 mL, 80 mL, 85 mL, 90 mL, or 95 mL), such as 12 weeks after administration.
The human subject may be male. The human subject may be female. The human subject may have an age of greater than or equal to 65 years. The human subject may have an age of less than 65 years. The human subject may be taking a background medication selected from one or more of a long-acting muscarinic antagonist (LAMA), a long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS). In some embodiments, the human subject is taking a LAMA. In some embodiments, the human subject is taking a LABA. In some embodiments, the human subject is taking an ICS.
In some cases, the human subject is not receiving a background medication. For instance, the human subject may not be taking a background medication, which background medication is a long-acting muscarinic antagonist (LAMA), a long-acting beta-agonist (LABA) or an inhaled corticosteroid (ICS). In some embodiments, the human subject is not taking a LAMA. In some embodiments, the human subject is not taking a LABA. In some embodiments, the human subject is not taking an ICS.
Preferably, the method comprises administering the compound to the human subject by inhalation from a nebuliser. Nebulisers aerosolise a liquid pharmaceutical composition into an aerosol that is inhaled into a human subject's respiratory tract. Examples of nebulisers include a soft mist nebuliser, a vibrating mesh nebuliser, a jet nebuliser and an ultrasonic wave nebuliser. Suitable nebuliser devices include the Philips I-neb™ (Philips), the Philips SideStream (Philips), the AeroNeb® (Philips), the Philips InnoSpire Go (Philips), the Pari LC Sprint (Pari GmbH), the AERxR™ Pulmonary Delivery System (Aradigm Corp) and the Pari LC Plus Reusable Nebuliser (Pari GmbH). The nebuliser may for instance be a PARI LC Sprint jet nebulizer with a PARI Vios® PRO Aerosol Delivery System PARI BOY® compressor. The compound may be inhaled via the nebuliser for from 1 to 15 minutes, for instance for from 5 to 10 minutes, or around 7 minutes.
In some embodiments, the methods disclosed herein comprises administering the compound to the human subject once, twice or three times per day, for instance twice or three times per day. The compound may be administered to the human subject by inhalation once, twice or three times a day. Preferably the method comprises administering the compound to the human subject by inhalation twice a day. The method may comprise administering a first dose of the compound in the morning (for instance within 3 hours following waking) and a second dose of the compound in the evening (for instance within 3 hours before bed). Typically, the morning and evening doses are administered from 10 to 14 hours apart, for instance about 12 hours apart.
In some embodiments, the compound is administered twice a day in two separate doses which are the same or similar. In some embodiments, the method may comprise administering the compound to the human subject twice a day in a first dose of from 2 to 4 mg and a second dose of from 2 to 4 mg.
In some embodiments, the method comprises administering two doses of the liquid pharmaceutical composition comprising about 3 mg ensifentrine free base to the human subject per day by inhalation. In some embodiments, the method preferably comprises administering a dose of about 3 mg of the compound to the human subject twice a day (3 mg BID) by inhalation. More preferably, the method comprises administering by nebuliser a dose of about 3 mg the compound to the human subject twice a day. Each dose may be 3.0 mg free base ensifentrine administered by nebulizer.
The compound may be used as a maintenance therapy. In some embodiments, the method comprises administering the compound to the human subject at least once per day for at least 8 weeks. The compound may be administered to the human subject at least once per day for at least 16 weeks, preferably for at least 24 weeks. The compound may be administered daily to the human subject for at least 1 year. The method may comprise administering the compound to the human subject at least once every 24 hours, preferably at least twice every 24 hours, for at least 8 weeks, preferably for at least 16 weeks, more preferably for at least 24 weeks.
Administering the liquid pharmaceutical composition to the human subject by inhalation may provide a blood plasma concentration of ensifentrine, which blood plasma concentration of ensifentrine has: a mean Cmax of from about 400 pg/mL to about 720 pg/mL; and/or a mean AUC0-tau of from about 2000 pg/mL*h to about 3000 pg/mL*h; and/or a mean Tmax at from about 0.8 hours to about 1.3 hours. The mean pharmacokinetic profile (or the pharmacokinetic profile achieved in an individual human subject) may be as further defined above for the liquid pharmaceutical composition.
Administering the liquid pharmaceutical composition to the human subject by inhalation may provide a mean increase in baseline FEV1 of at least 20 mL.
The disclosure also provides a liquid pharmaceutical composition as defined herein for use in a method of treating COPD as defined herein. Further provided is use of a liquid pharmaceutical composition as defined herein in the manufacture of a medicament for use in a method of treating COPD as defined herein.
The invention is described in more detail by the following Example.
A clinical study was conducted to determine the efficacy of ensifentrine in treating COPD compared with placebo. Ensifentrine was administered by nebuliser at a dose of 3 mg twice daily (BID) for 24 weeks. The study was a multi-centre, randomized, double-blind, parallel-group, placebo-controlled trial with around 800 patients and 5:3 randomization.
The study population included patients aged 40-80 years with moderate to severe COPD (FEV130%-70% p.n., FEV1/forced vital capacity (FVC) ratio<0.7, with mMRC≥2). The randomization stratified (a) the use of stable background maintenance LAMA or LABA therapy use (approx. 50%. yes or no) and (b) cigarette smoking (current or former). Inhaled corticosteroid (ICS) maintenance therapy was permitted in up to 20% of patients under certain provisions.
The primary endpoint of the study was change from baseline in average FEV1 area under the curve (AUC)0-12 h post-dose at week 12. Secondary endpoints of the study included: peak FEV1 over 4 hours post-dose at Week 12; morning trough FEV1 at Week 12; and other endpoints including moderate/severe COPD exacerbations frequency over 24 Weeks.
Baseline FEV1 is the mean of the two measurements taken before study medication on the day of first dosing, i.e., ≤40 minutes and just prior to dosing, both pre-dose on day 1.
Average FEV1 AUC0-12 h is defined as area under the curve over 12 hours of the FEV1, divided by 12 hours.
Plasma concentrations of ensifentrine for the assessment of pharmacokinetic (PK) parameters were measured using validated bioanalytical methods for ensifentrine in human plasma with LLOQ of 5 pg/mL.
Samples were taken on the following schedule:
The investigational product and placebo were provided in 2.5 mL unit dose format in an ampule and administered via a nebuliser. The formulation of the investigational product (ensifentrine suspension formulation comprising crystalline polymorph Form I of ensifentrine) and placebo are shown in Table 1 below.
The primary endpoint of average FEV1 (AUC)0-12 h at Week 12 was met. All subgroups showed improvement in lung function with ensifentrine that was statistically significant. The results are shown in Table 2.
Based on the samples taken during the trial, PK data was modelled for COPD patients with normal renal function. The final popPK model was used to predict parameter estimates in a virtual population of 50000 subjects (per covariate condition) for simulation of ensifentrine PK following nebulization of 3 mg in a population reflecting the population in the trial with normal renal function or mild renal impairment, or with moderate renal impairment. Uncertainty in fixed effects and covariance matrix parameters as well as residual variability were included in the simulations. The parameter uncertainty was accounted for by random resampling (without replacement) of 500 sets of parameter estimates from the bootstrap (750 replicates) in R to create 500 NONMEM simulation control streams. From each set of parameter estimates, the PK profiles for 100 subjects (for each covariate condition) were simulated with IIV and IOV from the covariance matrix and residual error in NONMEM. Individual subject concentrations were simulated using NONMEM version 7.4.3, and PK parameters were calculated using R version 3.4.0. The results are shown in Table 3.
It has been found that ensifentrine provides a statistically significant improvement in lung function in all subgroups of COPD patients in the study.
A mean Cmax of 522 pg/mL and a mean AUC of 2450 pg/mL*h were achieved in patients with COPD. These values were lower than the mean Cmax (852 pg/mL) and mean AUC (mean AUC0-∞of 5929 pg/mL*h) observed following administration of the composition to healthy patients, indicating lower systemic exposure of ensifentrine in COPD patients than in healthy patients.
This application claims the benefit of U.S. Provisional Application No. 63/502,977, filed May 18, 2023, which is incorporated herein by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 63502977 | May 2023 | US |
